Alitame is an artificial, high-intensity sweetener that is approximately 2,000 times sweeter than sucrose. It is a dipeptide derivative of aspartame, with the chemical formula C14H18N2O5. Alitame is synthesized by reacting aspartame with a specific amino acid, L-aspartic acid. It has been studied for its potential use as a low-calorie sweetener in food and beverages. Alitame is not readily metabolized in the body and does not contribute to caloric intake. However, there are concerns about its potential long-term effects on health, and its use is currently restricted in many countries. Alitame is not approved for use in the United States, but it is permitted in some other countries, such as Canada, Mexico, and Japan.'
alitame: nonnutritive sweetener; 2000 times sweeter than sucrose; formed from aspartic acid, alanine & an amide [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 64763 |
| CHEMBL ID | 2104004 |
| CHEBI ID | 184021 |
| SCHEMBL ID | 1324019 |
| MeSH ID | M0218643 |
| Synonym |
|---|
| AC-018 |
| 80863-62-3 |
| AKOS015840253 |
| aclame |
| alitame |
| CHEBI:184021 |
| (3s)-3-amino-4-oxo-4-[[(2r)-1-oxo-1-[(2,2,4,4-tetramethylthietan-3-yl)amino]propan-2-yl]amino]butanoic acid |
| d-alaninamide, l-alpha-aspartyl-n-(2,2,4,4-tetramethyl-3-thietanyl)- |
| pce8dae750 , |
| unii-pce8dae750 |
| l-alpha-aspartyl-n-(2,2,4,4-tetramethyl-3-thietanyl)-d-alaninamide |
| SCHEMBL1324019 |
| AKOS015920211 |
| (s)-3-amino-4-oxo-4-(((r)-1-oxo-1-((2,2,4,4-tetramethylthietan-3-yl)amino)propan-2-yl)amino)butanoic acid |
| alitame hydrate |
| ins-956(alitame) |
| cp-54802 |
| e-956(alitame anhydrous) |
| ins no.956(alitame) |
| CHEMBL2104004 |
| ins-956(alitame anhydrous) |
| e-956(alitame) |
| ins no.956(alitame anhydrous) |
| c14h25n3o4s |
| alitame [mart.] |
| d-alaninamide, l-.alpha.-aspartyl-n-(2,2,4,4-tetramethyl-3-thietanyl)- |
| (3s)-amino-n-((1r)-1-((2,2,4,4-tetramethyl-3-thietanyl)carbamoyl)ethyl)succinamic acid |
| alitame [mi] |
| IVBOUFAWPCPFTQ-SFYZADRCSA-N |
| DTXSID3043780 |
| alitame (parent) |
| (3s)-3-amino-4-([(1r)-1-methyl-2-oxo-2-[(2,2,4,4-tetramethyl-3-thietanyl)amino]ethyl]amino)-4-oxobutanoic acid |
| (s)-3-amino-4-oxo-4-(((r)-1-oxo-1-((2,2,4,4-tetramethylthietan-3-yl)amino)propan-2-yl)amino)butanoicacid |
| (s)-3-((r)-1-(2,2,4,4-tetramethylthietan-3-ylcarbamoyl)ethylcarbamoyl)-3-aminopropanoic acid |
| Q424676 |
| AS-40930 |
| l-?-aspartyl-n-(2,2,4,4-tetramethyl-3-thietanyl)-d-alaninamide; thietane, d-alaninamide deriv.; alitame; cp 54802 |
| d-alaninamide, l-a-aspartyl-n-(2,2,4,4-tetramethyl-3-thietanyl)- |
| alitame 100 microg/ml in water |
| Class | Description |
|---|---|
| dipeptide | Any molecule that contains two amino-acid residues connected by peptide linkages. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (48.02) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (16.67%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||